Current through Register Vol. XLI, No. 50, December 13, 2024
Section 69-7-22 - Continuous Quality Improvement Policies, Diversion Control Plan22.1. Each opioid treatment program shall maintain current quality assurance and quality control plans that include provisions for: 22.1.a. Regular and continuous staff education;22.1.b. An annual review, in consultation with the advisory council and the peer review committee, of program policies and procedures; and22.1.c. Consideration of ongoing input into program policies and procedures by patients regarding community concerns;22.1.d. Development and implementation of annual patient satisfaction surveys that include a review of patient satisfaction with operating hours and pricing of services;22.1.e. Adherence to universal infection control precautions promulgated by the Center for Disease Control;22.1.f. An ongoing assessment, measurement and monitoring of patient outcomes, treatment outcomes and the various processes including, but not limited to: 22.1.f.1. Reduction or elimination of the patient's use of illicit opioids, illicit drugs and the problematic use of licit drugs;22.1.f.2. Reduction or elimination of associated criminal activities;22.1.f.3. Reduction of the patient's behaviors contributing to the spread of infectious diseases; and22.1.f.4. Improvement of quality of life through the restoration of physical and behavioral health and functional status, including employment or volunteerism, as may be appropriate.22.2. The opioid treatment program shall annually collect outcome measurements and results of patient satisfaction surveys. The governing body and the advisory council shall review the results and submit the reports to the state authority.22.3. An opioid treatment program shall maintain a current "Diversion Control Plan" (DCP) as part of its quality assurance programs that contains specific measures to reduce the possibility of diversion of controlled substances from legitimate treatment use. The DCP shall assign specific responsibility to the medical and administrative staff of the opioid treatment program for carrying out the diversion control measures and functions described in the DCP. 22.3.a. The diversion control plan shall be reviewed and approved by the governing body, advisory council, peer review council and the state authority.22.3.b. Diversion control plans shall minimize the diversion of methadone or other opioid treatment medications to illicit use. The plan shall include: 22.3.b.1. Clinical and administrative continuous monitoring of the potential for and actual diversion including an investigation, tracking and monitoring system of incidents of diversion; and22.3.b.2. Proactive planning and procedures for problem identification, correction and prevention.